Clinical trials: Alzheimer Dementia
Alzheimer's Disease, Dementia
Specific Interventions for Agitation in Alzheimer's Disease
This study is aimed at investigating specific pharmacological interventions in the treatment of the disruptive, agitated behavior associated with Alzheimer's patients.
- Trial name
- NCT00018291
- Testing
- Risperidone, Gabapentin
- Where
- United States
- Sponsor
- US Department of Veterans Affairs
Alzheimer's Disease (AD)
Trial of Oxaloacetate in Alzheimer's Disease (TOAD)
The purpose of this study is to determine if oxaloacetate (OAA) is safe and tolerable at doses of up to 2 grams per day in people with Alzheimer's disease (AD).
- Trial name
- TOAD (NCT02593318)
- Testing
- Oxaloacetate (OAA) 1g, Oxaloacetate (OAA) 2g
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Russell Swerdlow
Alzheimer Disease, Psychotic Disorders
Antipsychotic Discontinuation in Alzheimer's Disease
In patients with Alzheimer's disease (AD) who respond to antipsychotic treatment of psychosis and/or agitation/aggression, the relapse risk after discontinuation is not established.
- Conditions
- Alzheimer Disease, Psychotic Disorders, Agitation, Aggression
- Trial name
- ADAD (NCT00417482)
- Testing
- risperidone
- Where
- 7 sites in United States
- Volunteers
- 180 people
- Sponsor
- New York State Psychiatric Institute
Physical Inactivity, Walking
Daily Goal Setting to Increase Everyday Physical Activity and Promote Cognitive Health in Midlife
The purpose of this study is to determine whether interaction with an adaptive Fitbit-based goal setting application can increase levels of everyday light intensity physical activity in middle-aged adults.
- Conditions
- Physical Inactivity, Walking, Cognitive Health, Self-regulation
- Trial name
- NCT05826379
- Testing
- Adaptive Daily Goal Setting, Interim Goal Prompt
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Milton S. Hershey Medical Center
Behavioral Variant of Frontotemporal Disorder (bvFTD), Phenocopy Frontotemporal Dementia (phFTD)
Premorbid Personality Profile of Patients With Cognitive and Behavioral Disorders
Damages in frontal area present in neurodegenerative disease (frontotemporal degeneration, frontal variant of Alzheimer disease) and in psychiatric disease (bipolar disorder) can affect behavior and cognition including social…
- Conditions
- Behavioral Variant of Frontotemporal Disorder (bvFTD), Phenocopy Frontotemporal Dementia (phFTD), Frontal Variant of Alzheimer Disease, Bipolar Disorder
- Trial name
- NCT06059313
- Testing
- Submission of the NEO-PI-3 questionnaire, Submission of the Interpersonal Reactivity Index questionnaire (IRI)
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Nantes University Hospital
Alzheimer Disease (AD)
[18F]F-AraG PET Imaging in Alzheimer's Disease
This study evaluates the use of [18F]F-AraG PET/CT imaging to quantify activated T cell involvement in patients with Alzheimer's disease (AD).
- Trial name
- NCT07611357
- Testing
- Drug: [18F]F-AraG (PET tracer)
- Volunteers
- 10 people
- Sponsor
- CellSight Technologies, Inc.
Alzheimer Disease
Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease
The study is a 24-week, randomized, double-blind, multi-site, placebo-controlled study in participants with mild cognitive impairment (MCI) or early dementia due to Alzheimer's disease (AD).
- Trial name
- PEGASUS (NCT03533257)
- Testing
- AMX0035
- Where
- 11 sites in United States
- Volunteers
- 95 people
- Sponsor
- Amylyx Pharmaceuticals Inc.
Postpartum
Effectiveness of a Smartphone App (PRIMI) to Promote Healthy Diet and Physical Activity After Pregnancy in Migrant Women
The PRIMI trial (Promoting Reproductive health In MIgrant women) is a randomized controlled trial evaluating the effectiveness of a smartphone app designed to promote a healthy diet, physical activity, and health literacy among…
- Trial name
- NCT06881277
- Testing
- Mobile phone based intervention
- Where
- Sweden
- Volunteers
- 200 people
- Sponsor
- Linkoeping University
Alzheimer's Disease
Convenience, Tolerability, and Safety of Change in the Administration of Rivastigmine From Capsules to a Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease
This study used two doses of rivastigmine transdermal patch (5 cm^2, 10 cm^2) to establish the feasibility of 2 switch schedules (with transdermal patch one-step dose titration or without dose titration) from rivastigmine…
- Trial name
- KAPA (NCT00549601)
- Testing
- Rivastigmine patch (4.6 mg/day switch to 9.5 mg/day), Rivastigmine patch (9.5 mg/day), Rivastigmine capsules (6 mg to 12 mg/day)
- Where
- Spain
- Volunteers
- 142 people
- Sponsor
- Novartis
Alzheimer's Disease, Dementia
Caregiver Solutions for Dementia Patients
The goal of this clinical trial is to test a mobile application amongst caregiver's supporting patients diagnosed with Alzheimer's Disease and Related Dementias (ADRD).
- Conditions
- Alzheimer's Disease, Dementia, Caregivers, Remote Monitoring
- Trial name
- NCT05888610
- Testing
- Digital Outpost
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Prepped Health LLC
Frontotemporal Dementia, Dementia
Care of Persons With Dementia in Their Environments (COPE) in Programs of All-Inclusive Care of the Elderly (PACE)
The protocol is organized into three Phases - In Phase I an online training program will be developed in "Care of Persons with Dementia in their Environments" (COPE) -an evidence-based bio-behavioral dementia program -using…
- Conditions
- Frontotemporal Dementia, Dementia, Multi-Infarct Dementia, Vascular Dementia
- Trial name
- NCT04165213
- Testing
- Care of Older Persons in their Environment (COPE) online module training
- Where
- United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Healthy Volunteers, Down Syndrome
Leucettinib-21 First-in-Human Phase 1 in Healthy Volunteers and Subjects With Down Syndrome and Alzheimer's Disease
Leucettinib-21 First-in-Human Phase 1 Study in 6 Parts: Single (Part 1 and 5) and Multiple (Part 3 and 6) Ascending Doses, and Food-Effect (Part 2) in Healthy Subjects, and Single Dose (Part 4) in People with Down Syndrome (DS)…
- Conditions
- Healthy Volunteers, Down Syndrome, Alzheimer's Disease
- Trial name
- LEUCETTA (NCT06206824)
- Testing
- Leucettinib-21
- Where
- France
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Perha Pharmaceuticals
Alzheimer Disease, Mild Cognitive Impairment
The LUCINDA Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's
The LUCINDA Trial is a three-site, phase II, randomized, double-blind, placebo-controlled study of leuprolide acetate (Eligard) in women with Mild Cognitive Impairment or Alzheimer's Disease taking a stable dose of a…
- Trial name
- LUCINDA (NCT03649724)
- Testing
- Eligard 22.5Mg Suspension for Injection
- Where
- 3 sites in United States
- Volunteers
- 86 people
- Sponsor
- Weill Medical College of Cornell University
Alzheimer Disease (AD), Frontotemporal Lobar Degeneration
ADDIA Proof-of-Performance Clinical Study
The objective of the ADDIA clinical Proof-of-Performance study is to validate the performance of ADDIA' blood biomarkers for diagnosis of Alzheimer's disease (AD).
- Conditions
- Alzheimer Disease (AD), Frontotemporal Lobar Degeneration, Dementia with Lewy Bodies (DLB), Parkinson Disease Dementia (PDD)
- Trial name
- ADDIA (NCT03030586)
- Testing
- volumetric MRI
- Where
- 13 sites in Belgium, France and 3 more
- Volunteers
- 821 people, healthy volunteers welcome
- Sponsor
- Amoneta Diagnostics SAS
Alzheimer's Disease - MCI
Noninvasive Brain Stimulation for pAD
Episodic memory refers to the conscious recalling of a personal experience and includes information of an event and the context in which the event took place.
- Trial name
- pADmemory (NCT05468268)
- Testing
- 20 Hz rTMS
- Where
- Italy
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Università degli Studi di Trento
Alzheimer's Disease
Elpipodect (MK-8189) Safety and Tolerability in Participants With Alzheimer's Disease With or Without Symptoms of Agitation-Aggression and/or Psychosis (MK-8189-017)
The purpose of this study is to evaluate the safety and tolerability of multiple ascending doses of elpipodect in participants with Alzheimer's Disease (AD) with or without symptoms of agitation-aggression and/or psychosis.
- Trial name
- NCT05227118
- Testing
- Elpipodect
- Where
- 8 sites in United States
- Volunteers
- 29 people
- Sponsor
- Merck Sharp & Dohme LLC
Alzheimer Disease
Memantine Treatment in Alzheimer's Disease Patients
The aim of this study is to investigate whether there will be any efficacy difference of Memantine treatment in different cognitive severity AD patients stratified with BPSD
- Trial name
- NCT03168997
- Testing
- Memantine Hydrochloride
- Volunteers
- 222 people
- Sponsor
- Wei Cuibai
Frontotemporal Dementia, Alzheimer Disease
Music, Social Attention, and Dementia
This is an exploratory mixed-methods control-treatment study to evaluate if participation in rhythmic musical activities improves social attention and connectedness in individuals living with mild to moderate bvFTD and AD, and…
- Trial name
- NCT06768996
- Testing
- Synchronous Rhythm Production, Solo Rhythm Production
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Alzheimer's Dementia (AD), Family Caregivers
Long-term Follow-up of Patients Included in the EYE-TAR(MA) Study.
EYE-TAR(MA)-Follow-Up is a non-interventionel, long-term follow-up study in subjects who participated to the study referred as EYE-TAR(MA) (NCT04730440) EYE-TAR(MA)-Follow-Up aims to evaluate the long-term impacts of the Training…
- Trial name
- NCT05254873
- Testing
- Long term follow-up
- Where
- Monaco
- Volunteers
- 7 people
- Sponsor
- Association de Recherche Bibliographique pour les Neurosciences
Dementia, Mild Cognitive Impairment
In-Home Technology for Caregivers of People With Dementia and Mild Cognitive Impairment
This study aims to develop and evaluate new in-home supportive technology that is designed to alleviate anxiety, burden, and loneliness in spousal and familial caregivers of individuals with Alzheimer's disease, other dementias…
- Conditions
- Dementia, Mild Cognitive Impairment, Alzheimer Disease
- Trial name
- NCT04206670
- Testing
- In-Home Technology System and Questionnaires, Waiting Control In-Home Technology System and Questionnaires
- Where
- United States
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- University of California, Berkeley
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.